Tofacitinib in Pregnancy: Assessing Pregnancy and Infant Outcomes, Cord Blood, and Breast Milk Concentrations
Clinical Gastroenterology and Hepatology · 2025
DOI: 10.1016/j.cgh.2024.01.019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2025. Verfasst von Katarina Mitrova und 6 weiteren Autor:innen. Beteiligte Einrichtung: IBD Clinical and Research Centre, ISCARE a.s., Prague, Czech Republic; Department of Paediatrics, 2nd Faculty of Medicine, Motol University Hospital,…. Hauptthemen laut MEDLINE: Piperidines, Pyrimidines, Milk, Human, Pregnancy Outcome. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 11 Literaturangaben.
Abstract (Originalsprache)
Janus kinase (JAK) inhibitors are effective anti-inflammatory agents for treatment of ulcerative colitis (UC).1 According to drug regulatory agencies and international guidelines, JAK inhibitors should be avoided during pregnancy and lactation.2-4 The existing evidence on safety of JAK inhibitors during pregnancy is scarce and almost exclusively limited to tofacitinib.4-7.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- IBD Clinical and Research Centre, ISCARE a.s., Prague, Czech Republic; Department of Paediatrics, 2nd Faculty of Medicine, Motol University Hospital, Charles University in Prague, Prague, Czech Republic.
- Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark; Center for Molecular Prediction of Inflammatory Bowel Disease, Department of Clinical Medicine, Aalborg University, Copenhagen,…
- Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
- Immunology Department, IBD Clinical and Research Centre, ISCARE a.s., Prague, Czech Republic; GENNET s.r.o., Prague, Czech Republic.
- Division of Gastroenterology, Department of Medicine, University of California, San Francisco, San Francisco, California.
- IBD Clinical and Research Centre, ISCARE a.s., Prague, Czech Republic; Department of Pharmacology, 1st Faculty of Medicine, Charles University in Prague, Czech Republic.
Zitieren
APA
Mitrova, K., Julsgaard, M., Augustijns, P., Cerna, K., Mahadevan, U., Duricova, D., & Pregnancy Study Group (2025). Tofacitinib in Pregnancy: Assessing Pregnancy and Infant Outcomes, Cord Blood, and Breast Milk Concentrations. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2024.01.019
Vancouver
Mitrova K, Julsgaard M, Augustijns P, Cerna K, Mahadevan U, Duricova D, et al. Tofacitinib in Pregnancy: Assessing Pregnancy and Infant Outcomes, Cord Blood, and Breast Milk Concentrations. Clinical Gastroenterology and Hepatology. 2025. doi:10.1016/j.cgh.2024.01.019
BibTeX
@article{Mitrova2025,
author = {Mitrova, Katarina and Julsgaard, Mette and Augustijns, Patrick and Cerna, Karin and Mahadevan, Uma and Duricova, Dana and Pregnancy Study Group, Pregnancy Study Group},
title = {Tofacitinib in Pregnancy: Assessing Pregnancy and Infant Outcomes, Cord Blood, and Breast Milk Concentrations},
journal = {Clinical Gastroenterology and Hepatology},
year = {2025},
doi = {10.1016/j.cgh.2024.01.019}
}
EUVIMED